Alzheon
General Information | |
Business: |
We are a clinical stage biopharmaceutical company with a late-stage program in Alzheimer’s disease and a discovery platform of small molecules for the inhibition of protein misfolding and aggregation in neurodegenerative disorders. Protein misfolding is an abnormal process in which a protein fails to fold in its normal configuration, rendering the protein toxic or inactive. Our goal is to develop disease modifying treatments for patients with Alzheimer’s and other neurological disorders by leveraging our expertise in inhibiting protein misfolding and aggregation. |
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 6 |
Founded: | 2013 |
Contact Information | |
Address | 111 Speen Street, Suite 306, Framingham, MA 01701, US |
Phone Number | (508) 861-7709 |
Web Address | http://www.alzheon.com |
View Prospectus: | Alzheon |
Financial Information | |
Market Cap | $81.3mil |
Revenues | $0 mil (last 12 months) |
Net Income | $-7.6 mil (last 12 months) |
IPO Profile | |
Symbol | ALZH |
Exchange | NASDAQ |
Shares (millions): | 6.0 |
Price range | $5.00 - $5.00 |
Est. $ Volume | $30.0 mil |
Manager / Joint Managers | ThinkEquity (A division of Fordham Financial Management)/ H.C. Wainwright & Co. |
CO-Managers | The Benchmark Company |
Expected To Trade: | |
Status: | Withdrawn |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |